Nicotinic antagonists

Ibogaine by David Dardashti Recommends Ibogaine Treatments to be Tailored to Individuals

Retrieved on: 
Friday, April 9, 2021

Ibogaine hydrochloride has proven to be the most effective treatment for opiate addiction, yet complications still arise.

Key Points: 
  • Ibogaine hydrochloride has proven to be the most effective treatment for opiate addiction, yet complications still arise.
  • They simply have a one size fits all method of Ibogaine treatment.
  • Ibogaine By David Dardashti has worked many years providing the most effective full treatment of ibogaine hydrochloride, having treated thousands of patients.
  • Ibogaine By David Dardashti has integrated many mathematical models, using principles of calculus, algebra, and statistics, used to effectively measure and predict the outcome of a single person's reaction to the ibogaine.

Myconic Capital Corp. Signs Letter of Intent for Acquisition of NY Ketamine Medical Practice, PLLC

Retrieved on: 
Monday, April 5, 2021

In otherwise treatment resistant depression patients, numerous studies have shown that intravenous ketamine therapy has an overall success rate of 70%.

Key Points: 
  • In otherwise treatment resistant depression patients, numerous studies have shown that intravenous ketamine therapy has an overall success rate of 70%.
  • Based on the success of its New York City clinic, NY Ketamine Infusions has opened an additional clinic in Long Island, NY (Melville).
  • Dr. Brooks also continues to act as a consultant for privately owned practices in Albany, NY and Madrid, Spain.
  • Myconic Capital Corp is an investment issuer with a diversified portfolio that is focused on emerging companies active in the high-tech, real estate, cannabis, mining and health & wellness sectors.

PharmaTher Advancing Research for Novel Microneedle Delivery of Ketamine

Retrieved on: 
Wednesday, March 24, 2021

The research will be led by Professor Ryan Donnelly, a world leader in the research of microneedle delivery technologies.

Key Points: 
  • The research will be led by Professor Ryan Donnelly, a world leader in the research of microneedle delivery technologies.
  • Most recently, Professor Donnelly's lab successfully completed research and published a paper titled Hydrogel-forming microneedle arrays as a therapeutic option for transdermal esketamine delivery.
  • His research validates the delivery of esketamine, theS(+)enantiomerof ketamine, in a novel microneedle patch which may overcome the drawbacks associated with ketamine administration in an intravenous or nasal spray format.1
    The proposed ketamine and KETABET MN patch offer a potential game-changing therapeutic solution for various unmet medical needs.
  • Despite its potential, ketamine has the potential for abuse and misuseleading to problems such as dissociative, hallucinogenic and amnesic effects6.

Dr. Ditzell Psychiatry, PLLC Opens New York Psychiatry Ketamine Treatment Center for Around-the-clock In-person Visits

Retrieved on: 
Thursday, March 18, 2021

Ketamine has been commonly used as a safe anesthetic in hospitals and medical settings for over a decade.

Key Points: 
  • Ketamine has been commonly used as a safe anesthetic in hospitals and medical settings for over a decade.
  • Ketamine Infusion Therapy is an IV procedure administered while undergoing a psychotherapy session with Dr. Ditzell himself.
  • The newly remodeled treatment center is located at 65 Broadway #901, New York City, NY.
  • Host of Psychs & The City Podcast, Dr. Ditzell has been featured in Forbes, Healthline, and is a medical reviewer for Insider.

American Society of Ketamine Physicians, Psychotherapists and Practitioners Recommends the Ethical Prescription and Administration of Ketamine

Retrieved on: 
Friday, March 12, 2021

One such example includes the unethical prescription and administration of IV ketamine in a home or even hotel room without an in-person evaluation by the prescribing provider.

Key Points: 
  • One such example includes the unethical prescription and administration of IV ketamine in a home or even hotel room without an in-person evaluation by the prescribing provider.
  • Their purpose is to serve as guidelines for safe and ethical administration of ketamine in practice.
  • (American Society of Ketamine Physicians, Psychotherapists, and Practitioners) In addition, ASKP3 composed a comprehensive Ethics Statement for ketamine providers in 2020 that is currently pending publication.
  • ASKP3: American Society of Ketamine Physicians, Psychotherapists, and Practitioners, 2020, ASKP3 Standards - ASKP.

Champignon Brands Restates Financial Statements and MD&A Files Listing Statement

Retrieved on: 
Friday, March 12, 2021

Complete details on the effect of the restatements are included in the notes to the Restated Financial Statements and in the MD&A.

Key Points: 
  • Complete details on the effect of the restatements are included in the notes to the Restated Financial Statements and in the MD&A.
  • The Restated Financial Statements and MD&A supersede the previously filed financial statements and MD&A.
  • The Interim Financial Statements and MD&A reflect the acquisition of AltMed Capital Corp. ("AltMed") on April 30, 2020 (the "Transaction").
  • Champignon Brands Inc. ( https://champignonbrands.com ) is a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions.

Relmada Therapeutics Announces Participation in the Oppenheimer 31st Annual Healthcare Conference

Retrieved on: 
Thursday, March 11, 2021

A live webcast of the fireside chat will be available via the investor section of the Company's website and at https://wsw.com/webcast/oppenheimer9/rlmd/2720795 .

Key Points: 
  • A live webcast of the fireside chat will be available via the investor section of the Company's website and at https://wsw.com/webcast/oppenheimer9/rlmd/2720795 .
  • Our experienced and dedicated team is committed to making a difference in the lives of patients and their families.
  • Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
  • Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Myconic Capital Corp. Signs Letter of Intent for Acquisition of Mindscape Ketamine & Infusions Therapy, PLLC

Retrieved on: 
Wednesday, March 10, 2021

After ketamine-based treatments helped to alleviate depression-related symptoms experienced by his wife, Dr. Henderson was inspired to open Mindscape to avail such treatments to the general public.

Key Points: 
  • After ketamine-based treatments helped to alleviate depression-related symptoms experienced by his wife, Dr. Henderson was inspired to open Mindscape to avail such treatments to the general public.
  • The Houston-based clinic, which administers ketamine through intravenous therapy (IV), is characterized by its spa-like atmosphere designed to put patients at ease.
  • Ketamine was first synthesized in 1962, and was successfully patented as a human anaesthetic in the United States in 1966.
  • We look forward to exploring the potential directions in which we can take Mindscape as ketamine treatments continue to gain acceptance and popularity across the United States.

Esketamine DPI: An NMDA Receptor Antagonists Being Developed by Celon Pharma - Global Emerging Insight and Market Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 9, 2021

The "Esketamine DPI - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Esketamine DPI - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • It acts as NMDA receptor antagonists and is being developed by Celon Pharma.
  • "Esketamine DPI - Emerging Insight and Market Forecast - 2030" report provides comprehensive insights about an investigational product for Treatment Resistant Bipolar Depression in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Ehave Inc. Files for KetaDash Trademark and to Uplist its Shares to the OTCQB

Retrieved on: 
Wednesday, March 3, 2021

Ehave recently announced plans to launch open testing of its KetaDASH ketamine IV therapy in the second quarter using advanced vein technology.

Key Points: 
  • Ehave recently announced plans to launch open testing of its KetaDASH ketamine IV therapy in the second quarter using advanced vein technology.
  • On March 1, 2021 Ehave successfully filed its application to uplist its shares on the OTCQB market.
  • The KetaDASH www.ketadash.com platform allows licensed ketamine clinics and patients who have been prescribed ketamine by a physician to administer the treatment at home intravenously.
  • Ben Kaplan, Chief Executive Officer of Ehave commented, The application for a U. S. Trademark is a key step in protecting our valuable brand and psychedelic medicine assets, most notably KetaDASH.